Atea Pharmaceuticals Stock Forecast
NASDAQ: AVIRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
AVIR analyst consensus
Consensus (3 analysts)
none
Avg. price target
$9.42+82.74%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Atea Pharmaceuticals (2026-10-08), 2 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $9.42, with a high estimate of $11.25 and a low estimate of $7.00. The average target implies upside of 82.7% from the current price of $5.16.
The spread between the highest and lowest targets is 60.7%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for AVIR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 67% |
| Hold | 1 | 33% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | +35.79% |
| Average target | $9.42 | +82.74% |
| High target | $11.25 | +118.23% |